These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35278836)

  • 1. Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan.
    Novick D; Rajan N; Wei A; Cheng R; Szende A; Baik R; Colman S
    Value Health Reg Issues; 2022 Jul; 30():76-82. PubMed ID: 35278836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Treatment Patterns and Health-Resource Utilization in Patients with Hepatocellular Carcinoma (HCC) Following Failure of Sorafenib: A Retrospective Chart Review of 127 Patients in South Korea.
    Novick D; Cho JM; Colman S; Szende A
    Drugs Real World Outcomes; 2022 Jun; 9(2):263-274. PubMed ID: 34905182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
    Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
    Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
    Yau T; Yao TJ; Chan P; Wong H; Pang R; Fan ST; Poon RT
    Oncologist; 2011; 16(9):1270-9. PubMed ID: 21885876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
    Hong YM; Yoon KT; Cho M
    BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
    Kuo YH; Wu IP; Wang JH; Hung CH; Rau KM; Chen CH; Kee KM; Hu TH; Lu SN
    Invest New Drugs; 2018 Apr; 36(2):307-314. PubMed ID: 28466374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
    Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
    Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Ramucirumab
    Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
    Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
    Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
    J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
    Kegasawa T; Sakamori R; Maesaka K; Yamada R; Tahata Y; Urabe A; Kodama T; Hikita H; Imanaka K; Ohkawa K; Hiramatsu N; Oshita M; Yamada Y; Inada M; Yakushijin T; Imai Y; Tatsumi T; Takehara T
    Dig Dis Sci; 2021 May; 66(5):1720-1729. PubMed ID: 32556820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
    Aly A; Malangone-Monaco E; Noxon V; Henriques C; Benavente F; Kim A
    Curr Med Res Opin; 2020 Nov; 36(11):1813-1823. PubMed ID: 32969741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.
    Huang CC; Chen HY; Chang RH; Liao PA; Lien HH; Hung CS; Yang SS; Hu JT
    Drug Des Devel Ther; 2019; 13():397-404. PubMed ID: 30774305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
    Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
    J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
    Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
    J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
    Gamstätter T; Weinmann A; Schadmand-Fischer S; Spies PR; Niederle IM; Schuchmann M; Galle PR; Wörns MA
    Onkologie; 2011; 34(10):538-42. PubMed ID: 21985853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.